Company news

Share this article:
Genstruct, a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology, announced it has entered into a master research agreement with Pfizer designed to cover current and future collaborations. The first collaboration under this new agreement is in the area of preclinical drug safety, focusing initially on a systems biology analysis of underlying mechanisms of drug-induced liver injury.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions